Tissue Array
Log In | My Account | Cart (0 items) - $0.00
US Biomax, Inc.
 

BR1503a

Breast cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases/150 cores, with IHC results of Her-2, ER, PR, AR, P53 and Ki67, 75 cases/150 cores, replaced by BR1503b
Unstained: $255.00 Add to Cart
H&E (BR1503as*): $255.00 Add to Cart

Microarray Panel:Breast invasive ductal carcinoma tissue microarray, containing 3 cases of adjacent normal breast tissue, 3 breast fibroadenoma, 2 breast cystosarcoma phyllodes, 7 breast intraductal carcinoma, 60 breast invasive ductal carcinoma, duplicate cores per case
Cores:150
Cases:75
Layout:15 cols × 10 rows
Core Diameter:1 mm
Thickness:5 µm
Quality Control:Anti-Actin confirmed
Applications:Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.

*Tissue Microarray Slide Types:

  • Unstained: unstained paraffin tissue microarray slide.
  • Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
  • H & E: Hematoxylin and Eosin stained tissue microarray slide.

Microarray Panel Display

 
Slide Label: US Biomax, Inc. Tissue Array
123456789101112131415 
A Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
B Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
C Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
D Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
E Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
F Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
G Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
H Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
I Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
J Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre Marked point
Legend: Bre - Breast

- Benign tumor, - Malignant tumor, - Malignant tumor, - Malignant tumor (stage I), - Malignant tumor (stage II), - Malignant tumor (stage IIIa), - Malignant tumor (stage IIIb), - Malignant tumor (stage IIa), - Malignant tumor (stage IIb), - NAT

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Grade Stage TNM AR ER PR P53 Ki67 HER2 Type †
A1 1 F 37 Breast Cancer adjacent normal breast tissue (sparse) – – – – +, 5% ++, 40% – – – NAT
A2 2 F 37 Breast Cancer adjacent normal breast tissue – – – +, 20% +, 5% ++, 40% – – – NAT
A3 3 F 43 Breast Cancer adjacent normal breast tissue (fibrofatty tissue and blood vessel) – – – +, 40% +, 10% +++, 40% – +++, 30% – NAT
A4 4 F 43 Breast Cancer adjacent normal breast tissue – – – +, 50% +, 60% +++, 40% – +++, 7% – NAT
A5 5 F 46 Breast Cancer adjacent normal breast tissue – – – +, 40% +, 40% +++, 20% – – – NAT
A6 6 F 46 Breast Cancer adjacent normal breast tissue (hyperplasia of breast) – – – +, 10% +, 30% +++, 5% – ++, 10% – NAT
A7 7 F 19 Breast Fibroadenoma – – – +, 10% – +++, 30% +, 1% +++, 25% + Benign
A8 8 F 19 Breast Fibroadenoma – – – ++, 40% – +++, 40% – +, 0.5% + Benign
A9 9 F 22 Breast Fibroadenoma – – – ++, 90% +++, 60% +++, 50% – +, 8% + Benign
A10 10 F 22 Breast Fibroadenoma – – – ++, 91% +++, 60% +++, 50% – +++, 8% + Benign
A11 11 F 54 Breast Fibroadenoma – – – – +, 10% – – ++, 5% – Benign
A12 12 F 54 Breast Fibroadenoma – – – – +, 15% – – ++, 10% – Benign
A13 13 F 69 Breast Cystosarcoma phyllodes – – – – ++, 10% +++, 10% +, 0.5% ++, 4% + Malignant
A14 14 F 69 Breast Cystosarcoma phyllodes – – – +, 25% ++, 10% +++, 10% – ++, 10% + Malignant
A15 15 F 49 Breast Cystosarcoma phyllodes (fibrous tissue and blood vessel) – – – – – – – – – Malignant
B1 16 F 49 Breast Cystosarcoma phyllodes (fibrous tissue and blood vessel) – – – – – – – – – Malignant
B2 17 F 58 Breast Intraductal carcinoma (sparse) – – TisN0M0 – – – – +++, 99% – Malignant
B3 18 F 58 Breast Intraductal carcinoma (fibrous tissue and blood vessel) – – TisN0M0 – – +++, 90% – – – Malignant
B4 19 F 45 Breast Intraductal carcinoma – – TisN0M0 +, 40% ++, 90% +++, 99% – ++, 10% – Malignant
B5 20 F 45 Breast Intraductal carcinoma – – TisN0M0 +, 65% ++, 90% – – ++, 15% – Malignant
B6 21 F 67 Breast Intraductal carcinoma – – TisN0M0 ++, 65% – – +++, 100% +++, 85% +++ Malignant
B7 22 F 67 Breast Intraductal carcinoma – – TisN0M0 ++, 70% – – +++, 100% +++, 40% +++ Malignant
B8 23 F 38 Breast Intraductal carcinoma (invasive ductal carcinoma) 2 – TisN0M0 ++, 70% +, 5% +++, 99% +, 5% ++, 15% + Malignant
B9 24 F 38 Breast Intraductal carcinoma with early infiltrate – – TisN0M0 +, 50% – +++, 90% +, 3% ++, 10% + Malignant
B10 25 F 43 Breast Intraductal carcinoma (invasive ductal carcinoma) 2 – TisN0M0 – – +++, 40% – – – Malignant
B11 26 F 43 Breast Intraductal carcinoma (invasive ductal carcinoma) 1 – TisN0M0 +, 70% ++, 90% ++, 30% ++, 40% +++, 45% – Malignant
B12 27 F 31 Breast Intraductal carcinoma – – TisN0M0 +, 15% +++, 85% – – ++, 8% – Malignant
B13 28 F 31 Breast Intraductal carcinoma (fibrous tissue and blood vessel) – – TisN0M0 – +++, 80% – – – – Malignant
B14 29 F 50 Breast Intraductal carcinoma – – TisN0M0 – – – ++, 80% ++, 80% ++ Malignant
B15 30 F 50 Breast Intraductal carcinoma – – TisN0M0 +, 1% – – +++, 95% ++, 85% ++ Malignant
C1 31 F 53 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 30% ++, 85% – +,35% ++, 85% – Malignant
C2 32 F 53 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 70% ++, 90% ++, 5% +, 20% ++, 85% – Malignant
C3 33 F 46 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 5% – – – +++, 95% + Malignant
C4 34 F 46 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 5% – +, 5% +, 4% +++, 90% + Malignant
C5 35 F 50 Breast Invasive ductal carcinoma 1 IIIb T4cN0M0 – – – – +++, 55% + Malignant
C6 36 F 50 Breast Invasive ductal carcinoma 1 IIIb T4cN0M0 – – +, 4% – +++, 65% + Malignant
C7 37 F 50 Breast Invasive ductal carcinoma 1 IIa T2N0M0 +++, 95% +++, 99% +++, 90% +, 1% ++, 8% – Malignant
C8 38 F 50 Breast Invasive ductal carcinoma 1 IIa T2N0M0 ++, 95% +++, 99% +++, 90% +, 1% +, 5% – Malignant
C9 39 F 54 Breast Invasive ductal carcinoma 1 IIa T2N0M0 +++, 99% – – +++, 95% +++, 15% +++ Malignant
C10 40 F 54 Breast Invasive ductal carcinoma 1 IIa T2N0M0 +++, 95% – – +++, 99% +++, 4% +++ Malignant
C11 41 F 45 Breast Invasive ductal carcinoma 1 II T1N0M0 ++, 90% – – +, 0.5% +++, 10% – Malignant
C12 42 F 45 Breast Invasive ductal carcinoma 1 II T1N0M0 ++, 95% – – +, 0.5% +++, 10% – Malignant
C13 43 F 52 Breast Invasive ductal carcinoma (sparse) – IIIa T2N2M0 ++, 50% +++, 15% – – ++, 20% – Malignant
C14 44 F 52 Breast Invasive ductal carcinoma (hyperplasia of breast) – IIIa T2N2M0 ++, 70% +++, 40% +++, 20% – – – Malignant
C15 45 F 64 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 95% – – ++, 40% ++, 55% +++ Malignant
D1 46 F 64 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 98% – – +++, 65% +++, 60% +++ Malignant
D2 47 F 51 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 – – – +++, 90% +, 70% – Malignant
D3 48 F 51 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 – – – +++, 100% +, 80% – Malignant
D4 49 F 47 Breast Invasive ductal carcinoma 2 IIb T3N0M0 +, 20% ++, 100% +++, 100% +, 8% ++-+++, 15% – Malignant
D5 50 F 47 Breast Invasive ductal carcinoma 2 IIb T3N0M0 +, 30% +++, 100% +++, 100% +, 15% +-++, 60% – Malignant
D6 51 F 50 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 +, 15% – – +, 10% +++, 40% +++ Malignant
D7 52 F 50 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 +, 25% – – – +++, 40% +++ Malignant
D8 53 F 48 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +++, 99% +++, 95% +++, 98% +, 3% +++,60% + Malignant
D9 54 F 48 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +++, 95% +++, 99% +++, 99% +, 5% +++,60% + Malignant
D10 55 F 38 Breast Invasive ductal carcinoma 2 IIb T2N1M0 ++, 90% – – ++, 95% +-++, 5% +++ Malignant
D11 56 F 38 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +, 10% – – ++, 99% +++, 30% +++ Malignant
D12 57 F 34 Breast Invasive ductal carcinoma 2 IIIb T4N0M0 +, 90% ++, 80% +, 5% +, 5% ++, 45% + Malignant
D13 58 F 34 Breast Invasive ductal carcinoma 2 IIIb T4N0M0 +, 90% ++, 60% +, 3% +, 8% ++, 30% + Malignant
D14 59 F 55 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 95% +++, 95% – – +++, 45% ++ Malignant
D15 60 F 55 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 99% +++, 99% – – +++, 40% ++ Malignant
E1 61 F 56 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 60% ++, 99% +++, 99% +, 1% +, 20% – Malignant
E2 62 F 56 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 60% ++, 99% +++, 99% +, 5% +, 10% – Malignant
E3 63 F 39 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 30% +++, 95% +++, 50% +++, 45% ++, 15% + Malignant
E4 64 F 39 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 85% +++, 90% ++, 15% +++, 65% ++, 35% + Malignant
E5 65 F 60 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 90% – – – +++, 85% +++ Malignant
E6 66 F 60 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 90% – – – +++, 70% +++ Malignant
E7 67 F 43 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +++, 100% +++, 99% +++, 98% – +++, 20% – Malignant
E8 68 F 43 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 99% +++,85% +++, 90% – +++, 8% – Malignant
E9 69 F 46 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 30% – – +++, 100% ++, 40% + Malignant
E10 70 F 46 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – +++, 100% ++, 50% + Malignant
E11 71 F 53 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 95% +++, 100% – – +++, 40% + Malignant
E12 72 F 53 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 99% +++, 100% – +, 8% ++, 45% + Malignant
E13 73 F 46 Breast Invasive ductal carcinoma (sparse) – IIIb T4N0M0 – – ++, 10% – – + Malignant
E14 74 F 46 Breast Invasive ductal carcinoma 2 IIIb T4N0M0 ++, 99% ++, 85% +++,85% +, 10% ++, 30% + Malignant
E15 75 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – No tissue No tissue +, 8% No tissue Malignant
F1 76 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – +, 40% ++, 45% ++, 80% ++, 35% + Malignant
F2 77 F 51 Breast Invasive ductal carcinoma 2 IIb T3N1M0 ++, 80% – +, 10% +++, 100% +++, 60% +++ Malignant
F3 78 F 51 Breast Invasive ductal carcinoma 2 IIb T3N1M0 ++, 70% – +, 5% +++, 100% +++, 60% +++ Malignant
F4 79 F 37 Breast Invasive ductal carcinoma 2 IIIb T4N2M0 +, 70% – – – ++, 5% +++ Malignant
F5 80 F 37 Breast Invasive ductal carcinoma 2 IIIb T4N2M0 +, 80% – – +, 15% +++, 30% +++ Malignant
F6 81 F 40 Breast Invasive ductal carcinoma 3 IIb T2N1M0 – – ++, 35% – +++, 40% + Malignant
F7 82 F 40 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – ++, 35% – +++, 40% + Malignant
F8 83 F 33 Breast Invasive ductal carcinoma 2 I T1N0M0 +, 30% – +++, 30% – +++, 10% + Malignant
F9 84 F 33 Breast Invasive ductal carcinoma 2 I T1N0M0 +, 40% – ++, 20% – +++, 1% – Malignant
F10 85 F 59 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 60% +++, 99% +, 35% +++, 80% ++, 25% – Malignant
F11 86 F 59 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 100% +++,100% – +++, 40% ++, 8% – Malignant
F12 87 F 43 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – ++, 75% ++-+++, 10% – Malignant
F13 88 F 43 Breast Invasive ductal carcinoma (sparse) – IIa T2N0M0 – – – – – – Malignant
F14 89 F 56 Breast Invasive ductal carcinoma 2 IIb T3N0M0 ++, 100% ++, 100% +, 15% – – + Malignant
F15 90 F 56 Breast Invasive ductal carcinoma 2 IIb T3N0M0 ++, 95% ++, 99% ++, 40% – +, 7% + Malignant
G1 91 F 67 Breast Invasive ductal carcinoma 2–3 I T1N0M0 ++, 5% +++, 1% +++, 4% – +++, 90% – Malignant
G2 92 F 67 Breast Invasive ductal carcinoma 2–3 I T1N0M0 – +, 5% – +, 25% +++, 85% – Malignant
G3 93 F 51 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 99% – – +, 90% ++, 45% – Malignant
G4 94 F 51 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 99% – – +, 90% ++, 45% – Malignant
G5 95 F 34 Breast Invasive ductal carcinoma 2–3 IIa T2N0M0 – – – +, 5% +++, 45% + Malignant
G6 96 F 34 Breast Invasive ductal carcinoma 2–3 IIa T2N0M0 – – – – +++, 45% + Malignant
G7 97 F 49 Breast Invasive ductal carcinoma 2 IIb T3N0M0 – – – – +, 10% ++ Malignant
G8 98 F 49 Breast Invasive ductal carcinoma 2 IIb T3N0M0 – – – – +, 30% ++ Malignant
G9 99 F 43 Breast Invasive ductal carcinoma (fibrofatty tissue and blood vessel) – I T1N0M0 – – – – – – Malignant
G10 100 F 43 Breast Invasive ductal carcinoma (breast tissue) – I T1N0M0 +, 50% – – +, 50% – – Malignant
G11 101 F 59 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – +++, 70% – – Malignant
G12 102 F 59 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – +++, 60% – – Malignant
G13 103 F 40 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +,10% – ++, 85% – +, 20% + Malignant
G14 104 F 40 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 20% – ++, 80% – +, 10% + Malignant
G15 105 F 46 Breast Invasive ductal carcinoma 2 I T1cN0M0 ++, 90% +, 70% +, 20% – – – Malignant
H1 106 F 46 Breast Invasive ductal carcinoma 2 I T1cN0M0 ++, 95% +, 99% ++, 75% +, 10% +, 20% – Malignant
H2 107 F 34 Breast Invasive ductal carcinoma 2 IIb T3N0M0 – – – – +, 25% + Malignant
H3 108 F 34 Breast Invasive ductal carcinoma 2 IIb T3N0M0 – – – – +, 15% + Malignant
H4 109 F 45 Breast Invasive ductal carcinoma 2 IIb T3N0M0 – – – +, 8% +, 25% – Malignant
H5 110 F 45 Breast Invasive ductal carcinoma 2 IIb T3N0M0 – – – +, 15% ++, 15% – Malignant
H6 111 F 63 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – – +, 5% – Malignant
H7 112 F 63 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – – +, 1% – Malignant
H8 113 F 35 Breast Invasive ductal carcinoma 3 IIa T2N0M0 – – – – +, 1% – Malignant
H9 114 F 35 Breast Invasive ductal carcinoma 3 IIa T2N0M0 – – – – ++, 40% – Malignant
H10 115 F 30 Breast Invasive ductal carcinoma 2 IIIb T4N0M0 +, 60% ++, 100% +++, 100% +, 10% +++, 35% – Malignant
H11 116 F 30 Breast Invasive ductal carcinoma 2 IIIb T4N0M0 ++, 90% +++, 100% +++, 100% +, 10% +++, 40% – Malignant
H12 117 F 43 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 40% +, 3% +++, 99% +, 10% +, 25% – Malignant
H13 118 F 43 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 40% +, 3% +++, 100% +, 8% +, 30% – Malignant
H14 119 F 54 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 99% ++, 80% +++, 100% – +++, 60% + Malignant
H15 120 F 54 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 80% +, 30% +++, 55% – +++, 55% + Malignant
I1 121 F 58 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +++, 99% – – +++, 80% ++, 13% +++ Malignant
I2 122 F 58 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +++, 90% – – +++, 85% +++, 20% +++ Malignant
I3 123 F 60 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – – +, 40% +++ Malignant
I4 124 F 60 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – – +, 25% +++ Malignant
I5 125 F 52 Breast Invasive ductal carcinoma 3 IIa T2N0M0 ++, 90% ++, 75% +++, 80% – – – Malignant
I6 126 F 52 Breast Invasive ductal carcinoma 3 IIa T2N0M0 ++, 90% ++, 45% +++, 60% – – – Malignant
I7 127 F 48 Breast Invasive ductal carcinoma 3 I T1N0M0 +, 20% – – – +++, 50% – Malignant
I8 128 F 48 Breast Invasive ductal carcinoma 3 I T1N0M0 +, 5% – – – ++, 20% – Malignant
I9 129 F 28 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – ++, 20% – +, 15% – Malignant
I10 130 F 28 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – ++, 90% – +, 15% – Malignant
I11 131 F 44 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – ++, 40% ++, 30% – Malignant
I12 132 F 44 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – – ++, 30% – Malignant
I13 133 F 45 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 5% – – – +++, 50% ++ Malignant
I14 134 F 45 Breast Invasive ductal carcinoma 2 IIa T2N0M0 +, 10% – – – +++, 20% ++ Malignant
I15 135 F 34 Breast Invasive ductal carcinoma 2–3 IIb T3N0M0 +, 5% – – ++, 85% +++, 90% ++ Malignant
J1 136 F 34 Breast Invasive ductal carcinoma 3 IIb T3N0M0 +, 5% – – +++, 90% +++, 95% ++ Malignant
J2 137 F 62 Breast Invasive ductal carcinoma 3 I T1N0M0 +, 10% – – +++, 98% +++, 80% – Malignant
J3 138 F 62 Breast Invasive ductal carcinoma 3 I T1N0M0 +, 20% – – +++, 99% +++, 75% – Malignant
J4 139 F 58 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – +++, 90% +++, 50% + Malignant
J5 140 F 58 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – +, 15% +++, 50% + Malignant
J6 141 F 56 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 55% – ++, 50% ++, 45% +++, 15% + Malignant
J7 142 F 56 Breast Invasive ductal carcinoma 2 IIa T2N0M0 ++, 60% – +++, 90% +, 5% +++, 40% + Malignant
J8 143 F 57 Breast Invasive ductal carcinoma 3 IIb T3N0M0 – – – – +++, 30% – Malignant
J9 144 F 57 Breast Invasive ductal carcinoma 3 IIb T3N0M0 – – – ++, 15% ++, 20% – Malignant
J10 145 F 63 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – ++, 15% +++, 45% – Malignant
J11 146 F 63 Breast Invasive ductal carcinoma 2 IIa T2N0M0 – – – ++, 1.5% +++, 40% – Malignant
J12 147 F 50 Breast Invasive ductal carcinoma 3 IIIa T2N2M0 +, 5% – – +, 1% +++, 90% – Malignant
J13 148 F 50 Breast Invasive ductal carcinoma 3 IIIa T2N2M0 – – – +, 1% +++, 90% – Malignant
J14 149 F 49 Breast Invasive ductal carcinoma 3 IIa T2N0M0 +++, 100% – – – +++, 55% – Malignant
J15 150 F 49 Breast Invasive ductal carcinoma 3 IIa T2N0M0 +++, 100% – – – +++, 60% – Malignant
– – M 58 Skin Malignant melanoma (tissue marker) – Malignant

† For precise diagnosis, refer to pathology description.

**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.

Staining Scoring: "-" - no staining; "+-" - borderline staining; "+" - weak staining; "++" - moderate staining; "+++" - strong staining; "%" - percentage of positive cells.

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis

Find overlapping cases with this tissue array:
© 2003 - 2011 US Biomax Inc., custsrv@biomax.us, Tel: (800) 935-1357 | Privacy Policy

Authorize.Net Seal Starfield Seal